文献速递瓣膜病与结构性心脏病

重度无症状主动脉瓣狭窄患者心肌纤维化与早期干预:EVOLVED随机临床试验洞察

Myocardial Fibrosis and Early Intervention in Asymptomatic Patients With Severe Aortic Stenosis: Insights From the EVOLVED Randomized Clinical Trial.
PubMed 文献 · JAMA Cardiol · 2026-01-01

该研究为EVOLVED随机临床试验的事后分析,纳入224例无症状重度主动脉瓣狭窄且心脏磁共振显示中壁纤维化的患者,中位随访42个月。结果显示纤维化负荷每增加1%与主要终点风险增加相关(HR 1.23),但早期干预与保守管理之间无显著交互作用;高纤维化负荷患者中早期干预组主要终点事件数值较低但未达统计学显著。

要点

  • 中壁纤维化负荷每增加1%,主要终点风险增加23%(HR 1.23,95%CI 1.08-1.37)。
  • 随机分组与纤维化负荷对主要终点无交互作用(P=0.39)。
  • 高纤维化负荷患者中早期干预组主要终点事件数值较低(20% vs 32%),但差异无统计学意义。

核心结论

  • 在无症状重度主动脉瓣狭窄患者中,较高的中壁纤维化负荷与不良结局相关。
  • 与临床监测相比,早期手术或经导管主动脉瓣置换的治疗效应未显示因中壁纤维化程度不同而存在异质性。

研究设计与样本

  • EVOLVED随机临床试验的事后分析,于2017年8月至2022年在英国和澳大利亚24个心脏中心开展。
  • 纳入224例无症状重度主动脉瓣狭窄且心脏磁共振显示中壁纤维化的患者,平均年龄73岁,平均主动脉瓣峰值流速4.3 m/s,中位随访42个月。

主要发现

  • 纤维化负荷每增加1%,主要终点风险增加(HR 1.23;95%CI 1.08-1.37),计划外主动脉瓣狭窄相关住院风险增加(HR 1.22;95%CI 1.03-1.40),全因死亡风险无显著增加(HR 1.17;95%CI 0.98-1.35)。
  • 随机分组与中壁纤维化负荷对主要终点(交互P=0.39)或次要终点无交互作用。
  • 高纤维化负荷(高于中位数)患者中,早期干预组主要终点事件12/59(20%),保守管理组17/53(32%)(HR 0.62;95%CI 0.29-1.28)。
  • 高纤维化负荷患者中,计划外主动脉瓣狭窄相关住院分别为4/59(7%)和13/53(25%)(HR 0.27;95%CI 0.08-0.77),全因死亡分别为9/59(15%)和10/53(19%)(HR 0.84;95%CI 0.33-2.07)。
  • 低纤维化负荷(低于中位数)患者中,两组主要终点无差异(HR 1.05;95%CI 0.39-2.86)。

临床怎么用

  • 对于无症状重度主动脉瓣狭窄患者,中壁纤维化负荷较高提示不良结局风险增加,可作为风险分层参考。
  • 早期手术或经导管主动脉瓣置换的获益未因中壁纤维化程度不同而显著改变,治疗决策仍需综合评估。

局限性

  • 本研究为随机临床试验的事后分析,样本量有限(224例),高纤维化负荷亚组事件数较少,结果需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Myocardial fibrosis burden has been associated with adverse clinical outcomes in symptomatic patients with aortic stenosis. OBJECTIVE: To determine whether midwall myocardial fibrosis burden is associated with adverse clinical outcomes in asymptomatic patients and whether those with more fibrosis derive greater benefit from early intervention. DESIGN, SETTING, AND PARTICIPANTS: This post hoc analysis of a randomized clinical trial was conducted between August 2017 and October 2022. The trial took place at 24 cardiac centers across the United Kingdom and Australia. Participants included asymptomatic patients with severe aortic stenosis and midwall fibrosis on cardiac magnetic resonance. These data were analyzed from October 2024 through June 2025. INTERVENTION: Early intervention with transcatheter or surgical aortic valve replacement. MAIN OUTCOMES AND MEASURES: Primary outcome was all-cause death or unplanned aortic stenosis-related hospitalization. Secondary outcomes included the individual components of the primary outcome. RESULTS: In 224 trial participants (mean [SD] age, 73 [9] years; 63 women and 161 men, and mean [SD] aortic valve peak velocity 4.3 [0.5] m per second) with a median follow-up of 42 months, fibrosis burden (per 1% increase) was associated with an increase in the primary end point (hazard ratio [HR], 1.23; 95% CI, 1.08-1.37) and its component of unplanned aortic stenosis-related hospitalizations (HR, 1.22; 95% CI, 1.03-1.40) but not all-cause death (HR, 1.17; 95% CI, 0.98-1.35). There were no interactions between randomization arm and the midwall fibrosis burden for the primary (P for interaction = .39) or secondary end points. In patients with high fibrosis burden above the median, the primary end point occurred in 12 of 59 (20%) of those randomized to early intervention and 17 of 53 (32%) of those randomized to guideline-directed conservative management (HR, 0.62; 95% CI, 0.29-1.28). For the individual components, all-cause death occurred in 9 (15%) and 10 (19%) patients, respectively (HR, 0.84; 95% CI, 0.33-2.07), and unplanned aortic stenosis-related hospitalization in 4 (7%) and 13 (25%) patients respectively (HR, 0.27; 95% CI, 0.08-0.77). In patients with low fibrosis burden below the median, there were no differences in the primary outcome (HR, 1.05; 95% CI, 0.39-2.86) or its components between intervention groups. CONCLUSIONS AND RELEVANCE: In this study, in asymptomatic patients with severe aortic stenosis, higher midwall fibrosis burden was associated with adverse outcomes. There was no demonstrable heterogeneity by the degree of midwall fibrosis for the treatment effects of early surgical or transcatheter aortic valve replacement compared to clinical surveillance. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03094143.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Craig NJ, Loganath K, Everett RJ, et al. Myocardial Fibrosis and Early Intervention in Asymptomatic Patients With Severe Aortic Stenosis: Insights From the EVOLVED Randomized Clinical Trial. JAMA Cardiol. 2026. PMID: 41984459. doi:10.1001/jamacardio.2026.0654

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。